Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference



 Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference

PR Newswire

CARLSBAD, Calif., May 13, 2013

CARLSBAD, Calif., May 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS), the leader in antisense therapeutics, today announced that
management will present a company overview at the 2013 UBS Global Healthcare
Conference on Monday, May 20, 2013 at 9:00 a.m. ET in New York, NY.

A live audio webcast of the presentation will be available on the "Investors &
Media" section of the Company's Web site, www.isispharm.com.  A replay will be
available on the Isis Web site within 48 hours and will be archived for a
limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners.  Isis'
broad pipeline consists of 28 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product,
KYNAMRO™, in the United States for the treatment of patients with HoFH.
 Genzyme is also pursuing marketing approval of KYNAMRO in other markets. 
Isis' patents provide strong and extensive protection for its drugs and
technology.  Additional information about Isis is available at
www.isispharm.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding Isis'
business and the therapeutic potential of Isis' technologies and products in
development.  Any statement describing Isis' goals, expectations, financial or
other projections, intentions or beliefs, including the commercial potential
of KYNAMRO, is a forward-looking statement and should be considered an at-risk
statement.  Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such drugs. 
Isis' forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause its results to differ materially
from those expressed or implied by such forward-looking statements.  Although
Isis' forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors currently
known by Isis.  As a result, you are cautioned not to rely on these
forward-looking statements.  These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form 10-K for the
year ended December 31, 2012, and its most recent quarterly report on Form
10-Q, which are on file with the SEC. Copies of these and other documents are
available from the Company.  In this press release, unless the context
requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis
Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. 
KYNAMRO™ is a trademark of Genzyme Corporation.

 

SOURCE Isis Pharmaceuticals, Inc.

Website: http://www.isispharm.com
Contact: D. Wade Walke, Ph.D., Executive Director, Corporate, Communications
and Investor Relations, 760-603-2741; or Amy Blackley, Ph.D., Associate
Director, Corporate Communications, 760-603-2772
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement